EPCT-01. PHASE I STUDY OF DAY101 (TAK580) IN CHILDREN AND YOUNG ADULTS WITH RADIOGRAPHICALLY RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMA (LGG)

BACKGROUND: We report a phase I study examining pharmacokinetics, safety and recommended dosage of the type 2 RAF inhibitor DAY101 in children/young adults with radiographically recurrent/progressive LGGs harboring MAPK pathway alterations. METHODS: Applying a 3 + 3 design, patients < 18 years of...

Descripción completa

Detalles Bibliográficos
Autores principales: Wright, Karen, Krzykwa, Emily, Greenspan, Lianne, Chi, Susan, Yeo, Kee Kiat, Mueller, Sabine, Prados, Michael, Haas-Kogan, Daphne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Early Phase Clinical Trials
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715228/
http://dx.doi.org/10.1093/neuonc/noaa222.126

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715228/
http://dx.doi.org/10.1093/neuonc/noaa222.126

Ejemplares similares